Clinical evidence shows GLP-1 receptor agonists improve liver function, reduce fat accumulation, and decrease inflammation in NAFLD, but have not yet demonstrated the ability to reverse liver fibrosis.
Steatosis and inflammation improved, fibrosis notGLP-1 drugs address metabolic drivers of NAFLD but have not demonstrated the ability to reverse established liver scarring
What the researchers found
Clinical studies show GLP-1 receptor agonists in NAFLD improve: liver function tests (ALT/AST), hepatic steatosis (fat accumulation) on histology, and hepatic inflammation on histology. However, they have not demonstrated improvement in liver fibrosis. The review suggests two key directions: early use in non-fibrotic NAFLD to prevent fibrosis progression, and combination therapy with other medications for advanced disease where additive or synergistic effects may be possible.
Why it matters
NAFLD has no FDA-approved treatment (at time of this review), and it's the fastest-growing cause of liver transplantation. GLP-1 drugs are already widely prescribed for diabetes and obesity — many of the same patients who have NAFLD. Understanding that these drugs help some but not all aspects of liver disease is critical for setting appropriate clinical expectations and designing combination treatment strategies.
How the study worked
Narrative review of selected clinical studies examining GLP-1 receptor agonist effects on NAFLD outcomes, including liver function tests and histological endpoints (steatosis, inflammation, fibrosis).
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. The included studies varied in design, patient populations, GLP-1 drugs used, and outcome measures. Most studies had relatively short follow-up periods, which may be insufficient to detect fibrosis changes. The term NAFLD has since been updated to MASLD/MASH in clinical nomenclature. More recent data (post-2023) may have changed some conclusions.
How to read the evidence
This is a narrative review of clinical studies, providing a moderate-quality synthesis. The evidence for steatosis and inflammation improvement is relatively consistent, while the null fibrosis finding may reflect short study durations or the biology of fibrosis reversal rather than drug inefficacy.
When this study was published
Published in 2023, this review predates some important developments including resmetirom approval for NASH and newer data on semaglutide in liver disease trials.
The bigger picture
The search for effective NAFLD treatments is one of hepatology's biggest challenges. GLP-1 drugs address the metabolic root causes (obesity, insulin resistance) and improve early disease markers, but their inability to reverse established fibrosis means they may not be sufficient alone for advanced disease. This gap is driving interest in combination approaches — GLP-1 drugs with FXR agonists, FGF21 analogues, or other fibrosis-targeting agents.
Questions still open
- Could earlier initiation of GLP-1 therapy in NAFLD patients prevent fibrosis from ever developing?
- What combination of GLP-1 drugs with fibrosis-targeting agents would be most effective for advanced NAFLD/NASH?
- Do newer GLP-1 drugs or dual/triple agonists show better fibrosis outcomes than earlier agents?
Common questions
Can GLP-1 drugs cure fatty liver disease?
Should all NAFLD patients take GLP-1 drugs?
Read the original research
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
Expert review of clinical pharmacology, 16(11), 1063-1072
Citation
Tsiampali, Chara; Papaioannidou, Paraskevi; Goulas, Antonis; Polyzos, Stergios A. (2023). The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.. Expert review of clinical pharmacology, 16(11), 1063-1072. https://doi.org/10.1080/17512433.2023.2274536